Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Abbott Laboratories is a global healthcare company specializing in medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. Its competitive position is strengthened by a diverse product portfolio, including the FreeStyle Libre glucose monitoring system and a robust pipeline in cardiovascular devices, primarily in North America and Europe.
Abbott generates revenue through the sale of medical devices, diagnostics, and nutritional products, leveraging its strong brand recognition and innovative technologies. The company benefits from pricing power due to its established market presence and the critical nature of its products, particularly in diabetes care and cardiovascular health.
Regulatory approvals for new medical devices and diagnostics
Sales growth in the FreeStyle Libre product line
Market share changes in the diabetes care segment
Global healthcare spending trends
Technological disruption in medical devices and diagnostics
Regulatory changes affecting product approvals and market access
Intense competition from other medical device manufacturers
Emerging players in the diabetes care market
Moderate debt levels could impact financial flexibility if market conditions worsen
moderate - Abbott's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles and consumer confidence.
Rising interest rates can increase financing costs for Abbott, potentially impacting capital expenditures and valuation multiples, especially in its capital-intensive medical devices segment.
minimal - Abbott's operations are not heavily reliant on credit markets, given its strong cash flow generation and manageable debt levels.
growth - investors are likely attracted to Abbott for its innovative product pipeline and growth potential in high-demand healthcare segments.
moderate - historical volatility is in line with industry averages, reflecting both growth prospects and regulatory risks.
